Samsung Biologics Co.,Ltd. (KRX:207940)

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Domestic Revenue	371.88B	558.09B
Domestic Revenue Growth	-33.37%	387.12%
Europe Revenue	2.37T	2.04T
Europe Revenue Growth	16.31%	-13.51%
USA Revenue	1.73T	822.63B
USA Revenue Growth	110.78%	-15.29%
Other Geographic Revenue	83.43B	80.66B
Other Geographic Revenue Growth	3.44%	-68.38%

Revenue Breakdown

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Contract Development and Manufacturing Organization (CDMO) Revenue	4.56T	3.50T
Contract Development and Manufacturing Organization (CDMO) Revenue Growth	30.30%	30.77%
Biopharmaceutical Development and Commercialization Revenue	-	1.54T
Biopharmaceutical Development and Commercialization Revenue Growth	-	50.71%

Revenue Breakdown 2

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Product Revenue	4.36T	3.38T
Product Revenue Growth	28.93%	-0.66%
Other Revenue	198.72B	116.72B
Other Revenue Growth	70.26%	-59.98%

EBIT

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Contract Development and Manufacturing Organization (CDMO) Operating Profit	2.07T	1.32T
Contract Development and Manufacturing Organization (CDMO) Operating Profit Growth	56.60%	21.43%
Biopharmaceutical Development and Commercialization Operating Profit	-	200.69B
Biopharmaceutical Development and Commercialization Operating Profit Growth	-	688.24%

Updated Dec 31, 2025. Data Source: Fiscal.ai.